Nigeria Approves ₦24 Billion in Tax Waivers for 75 Healthcare Manufacturers
President Bola Tinubu says the incentives are supporting domestic production of medicines, medical equipment, diagnostics and other essential health products.

ABUJA, — The Federal Government has approved more than ₦24 billion in tax and tariff waivers for 75 healthcare manufacturers between January 2025 and June 2026, as Nigeria intensifies efforts to expand domestic production of medicines, medical equipment and other essential health products.
The disclosure was made by President Bola Ahmed Tinubu in an opinion article published on Monday, November 16, titled Why We Are Building Nigeria's Healthcare Economy. He said the incentives were introduced to encourage investment in local manufacturing, strengthen the healthcare value chain and reduce the country's dependence on imported medical products.
The waivers were provided under an Executive Order signed in June 2024, which introduced tax and tariff relief on specified machinery, equipment and production inputs used in healthcare manufacturing.
In practical terms, the waivers allow eligible manufacturers to import certain approved machinery, equipment and production materials without paying some of the taxes and import charges that would normally increase their operating costs. These may include import duties, Value Added Tax and applicable excise duties on qualifying items.
Some of the materials covered include Active Pharmaceutical Ingredients (APIs), which are the substances responsible for the therapeutic effects of medicines, and excipients, which are additional ingredients used to produce tablets, capsules and other pharmaceutical products.
For example, a Nigerian pharmaceutical company importing approved raw materials to manufacture medicines would normally face additional costs from applicable import charges and taxes. With the relevant exemptions, the company can save some of that money and potentially use it to expand production, purchase equipment or improve its manufacturing facilities.
The ₦24 billion therefore represents the value of approved tax and tariff relief, not cash payments made directly to the companies. The government's intention is to make local production more affordable and encourage manufacturers to invest in Nigeria.
Ten factories and manufacturing lines commissioned
The initiative is part of the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC), established in October 2023 to attract investment into Nigeria's healthcare manufacturing and services sectors.
President Bola Ahmed Tinubu also disclosed that ten factories or manufacturing lines producing priority healthcare products had been commissioned, including six in 2026.
The facilities cover the production of medicines, diagnostic tests, medical oxygen and mosquito nets. These products are important for improving access to essential healthcare supplies and strengthening Nigeria's ability to respond to public health challenges.
One area highlighted by the President was the local production of insecticide-treated mosquito nets, which play an important role in preventing malaria.
He said international manufacturer Vestergaard had announced plans to begin operations at Health Textiles Nigeria in September 2026 following an agreement with the Presidential Initiative for Unlocking the Healthcare Value Chain in 2024.
He also identified Harvestfield, a Nigerian company already producing dual-ingredient mosquito nets, as part of the country's expanding manufacturing capacity.
According to the President, the companies are expected to produce more than ten million mosquito nets annually when operating at full scale and employ over 600 people.
Technology transfer and diagnostic production
The administration is also encouraging technology transfer to strengthen the production of diagnostic products within Nigeria.
President Bola Ahmed Tinubu highlighted an agreement involving Codix Bio and the Medicines Patent Pool, supported by the World Health Organisation, for the transfer of technology from South Korean company SD Biosensor to enable local production of rapid diagnostic tests.
He also mentioned NASENI-Troment as another company involved in deploying technology for diagnostic kit manufacturing.
These developments are intended to improve the availability of diagnostic products used to identify diseases and support medical treatment.
Beyond manufacturing, the President said the government was prioritising investments in advanced diagnostics, cancer treatment and specialist healthcare services. The objective is to improve access to treatment within Nigeria and reduce the need for patients to travel abroad for specialised medical care.
Challenges remain for local manufacturers
Despite the reported progress, expanding domestic healthcare production will require more than tax incentives. Manufacturers must also have access to reliable electricity, financing, skilled workers, modern equipment and dependable supplies of production materials.
Local products must meet the required safety and quality standards to compete with imported alternatives and earn the confidence of healthcare providers and patients.
The administration has also highlighted the importance of improving purchasing arrangements through Medipool, a group purchasing organisation designed to consolidate demand for medicines and other healthcare commodities. The initiative is expected to help create more predictable demand for manufacturers and improve purchasing efficiency.
For Nigeria, the success of the programme will depend on whether the approved incentives and announced investments lead to sustained production, reliable supplies and lower costs for patients.
While the ₦24 billion in approved waivers represents government support for the industry, the longer-term measure of success will be the availability of quality, locally manufactured healthcare products across the country.

